Izumi Horikawa

Senescence-inhibitory Δ133p53α counteracts accelerated ageing and mortality

This study shows that Δ133p53α extends lifespan and improves tissue health in a progeria mouse model, suggesting potential therapeutic applications for both progeria and ageing.

The senescence-inhibitory p53 isoform Δ133p53α represses the proinflammatory chemokine CXCL10 in progeria model mice and naturally aged mice

This study shows that Δ133p53 reduces CXCL10 levels in progeria and aged mice, linking it to anti-inflammatory effects.

SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer

This study shows that knocking down SRSF3 induces cellular senescence in NSCLC cells, including those without targetable mutations, suggesting a potential new therapeutic strategy.

Pharmacologic activation of Δ133p53α reduces cellular senescence in progeria patients-derived cells

This study shows that celastrol and AZD1981 increase Δ133p53 levels and reduce senescence and IL-6 secretion in HGPS-derived fibroblasts, independent of progerin levels.

Δ133p53α Protects Human Astrocytes from Amyloid-Beta Induced Senescence and Neurotoxicity

This paper shows that Δ133p53α protects human astrocytes from amyloid-beta-induced senescence and neurotoxicity by preventing DNA damage and SASP.